The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

GSK plc GSK announced that the FDA has approved Exdensur (depemokimab-ulaa), an ultra-long-acting IL-5–targeting biologic, as ...

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...

If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist ...

WASHINGTON - The Food and Drug Administration has approved Exdensur as an add-on maintenance treatment for patients aged 12 ...

Please provide your email address to receive an email when new articles are posted on . In 2011, 23.2% of adults with asthma experienced cost-related medication nonadherence vs. 13.1% in 2022. The ...

Despite a declining trend, the number of adults in the U.S. who say they did not adhere to their asthma treatment because of costs remains high, according to an observational study. From 2011-2022, ...

In 2017, an expert commission organized by the Lancet examined the current state of asthma care. That commission identified poor medication adherence as one of the principal barriers standing between ...

(NewsNation) — A Wisconsin family is suing Walgreens and insurance companies after they say the rising costs of asthma medication led to the death of their 22-year-old son last year. Cole ...

Study results show that patients with chronic obstructive pulmonary disease (COPD) and comorbid asthma may have a greater risk of hospitalization from COVID-19 if they use bronchodilators or steroids ...